305 related articles for article (PubMed ID: 10874052)
41. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis.
Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):111-118. PubMed ID: 28339364
[TBL] [Abstract][Full Text] [Related]
42. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
[TBL] [Abstract][Full Text] [Related]
43. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
44. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
45. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
Brijker F; Magee CC; Tervaert JW; O'Neill S; Walshe JJ
Clin Nephrol; 1999 Dec; 52(6):344-51. PubMed ID: 10604641
[TBL] [Abstract][Full Text] [Related]
46. [Systemic ANCA-associated vasculitis--diagnosis and therapy].
Eisenberger U; Hess C
Ther Umsch; 2008 May; 65(5):295-301. PubMed ID: 18622935
[TBL] [Abstract][Full Text] [Related]
47. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.
Léger JM; Chassande B; Musset L; Meininger V; Bouche P; Baumann N
Brain; 2001 Jan; 124(Pt 1):145-53. PubMed ID: 11133794
[TBL] [Abstract][Full Text] [Related]
48. Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with Eosinophilic Granulomatosis with Polyangiitis (EGPA).
Pecoraro A; Crescenzi L; Carucci L; Genovese A; Spadaro G
Int Immunopharmacol; 2017 Apr; 45():13-15. PubMed ID: 28152445
[TBL] [Abstract][Full Text] [Related]
49. Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis.
Yoo J; Kim HJ; Jung SM; Song JJ; Park YB; Lee SW
Int J Rheum Dis; 2017 Oct; 20(10):1593-1605. PubMed ID: 28766857
[TBL] [Abstract][Full Text] [Related]
50. New aspects in the management of ANCA-positive vasculitis.
Levy J
Nephrol Dial Transplant; 2001 Jul; 16(7):1314-7. PubMed ID: 11427616
[No Abstract] [Full Text] [Related]
51. [A preliminary study of the significance of autoantibodies against light chain of myeloperoxidase on pulmonary damages in myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis].
Zhang L; Shuai Z; Hu Z; Zhang M; Chen S
Zhonghua Nei Ke Za Zhi; 2015 Jun; 54(6):511-6. PubMed ID: 26359012
[TBL] [Abstract][Full Text] [Related]
52. Part 3: Newer therapies for ANCA-associated vasculitis.
Jayne D
Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S77-9. PubMed ID: 17428377
[No Abstract] [Full Text] [Related]
53. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?
Aries PM; Hellmich B; Gross WL
Clin Rev Allergy Immunol; 2005 Dec; 29(3):237-45. PubMed ID: 16391399
[TBL] [Abstract][Full Text] [Related]
54. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.
Birck R; Warnatz K; Lorenz HM; Choi M; Haubitz M; Grünke M; Peter HH; Kalden JR; Göbel U; Drexler JM; Hotta O; Nowack R; Van Der Woude FJ
J Am Soc Nephrol; 2003 Feb; 14(2):440-7. PubMed ID: 12538745
[TBL] [Abstract][Full Text] [Related]
55. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.
Roccatello D; Baldovino S; Alpa M; Rossi D; Napoli F; Naretto C; Cavallo R; Giachino O
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S67-71. PubMed ID: 18799057
[TBL] [Abstract][Full Text] [Related]
56. Primary systemic vasculitis.
Savage CO; Harper L; Adu D
Lancet; 1997 Feb; 349(9051):553-8. PubMed ID: 9048802
[No Abstract] [Full Text] [Related]
57. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
[TBL] [Abstract][Full Text] [Related]
58. Serum soluble interleukin 2 receptor levels in anti-neutrophil cytoplasmic autoantibodies--positive systemic vasculitis.
Lai KN; Lockwood CM
Postgrad Med J; 1993 Sep; 69(815):708-11. PubMed ID: 8255836
[TBL] [Abstract][Full Text] [Related]
59. [Therapeutic effect and clinical findings in patients with MPO-ANCA associated vasculitis syndrome].
Yoshida A; Takeda A; Fukuda M; Toda S; Morozumi K
Ryumachi; 2000 Feb; 40(1):1-8. PubMed ID: 10783659
[TBL] [Abstract][Full Text] [Related]
60. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH; Wright MN; Herrmann K; Laudien M; Nölle B; Reinhold-Keller E; Bremer JP; Moosig F; Holle JU
Arthritis Rheumatol; 2016 Dec; 68(12):2953-2963. PubMed ID: 27333332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
